Literature DB >> 2427810

Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

W H van Gilst, P A de Graeff, H Wesseling, C D de Langen.   

Abstract

The effects of the angiotensin converting enzyme (ACE) inhibitors captopril, enalapril, HOE 498, and its prodrug on reperfusion arrhythmias after 15 min of coronary ligation were investigated in the isolated rat heart. Drug concentrations were equipotent in their effect on angiotensin I pressor response. Furthermore, the effect of indomethacin on ACE inhibition with captopril was studied. Upon reperfusion, ventricular fibrillation occurred in all untreated hearts, in all prodrug HOE 498-treated hearts (15 micrograms/ml), and in 4 of 6 of the enalapril-treated (8 micrograms/ml) hearts. In contrast, in only 2 of 6 (p less than 0.002) of the HOE 498-treated hearts (15 micrograms/ml) and in none (p less than 0.001) of the captopril-treated hearts (80 micrograms/ml) did ventricular fibrillation occur. A massive purine overflow was observed in untreated hearts upon reperfusion. This overflow was significantly reduced by captopril and HOE 498, whereas enalapril and prodrug HOE 498 had no significant effect. Concomitantly, the pressure-rate index was severely impaired after 30 min of reperfusion in the untreated, enalapril, and prodrug HOE 498 groups (33 +/- 9, 52 +/- 11, and 48 +/- 12% of initial values, respectively), but captopril and HOE 498 significantly reduced the impairment of mechanical function (124 +/- 9% and 98 +/- 9%, respectively). In contrast to enalapril and prodrug HOE 498, captopril and HOE 498 markedly reduced noradrenaline overflow during the first minutes of reperfusion. No angiotensin II was detectable in the coronary effluent of untreated hearts.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427810

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  30 in total

1.  Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril.

Authors:  A Cargnoni; L Comini; P Bernocchi; T Bachetti; C Ceconi; S Curello; R Ferrari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

Review 4.  Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.

Authors:  V J Dzau
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors.

Authors:  G Bönner
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 6.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

7.  Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

Authors:  D W Cushman; F L Wang; W C Fung; G J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial.

Authors:  F X Kleber; L Niemöller; W Doering
Journal:  Br Heart J       Date:  1992-04

9.  Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.

Authors:  X Liu; R M Engelman; J A Rousou; G A Cordis; D K Das
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

10.  Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury.

Authors:  H Suzuki; A Matsumori; Y Matoba; B S Kyu; A Tanaka; J Fujita; S Sasayama
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.